Biblio Discovery — Demo Discovery Service

45 results for "Xiuning Le"

Showing 1–20 · 1.01 seconds · RSS

  1. Journal Article

    Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

    Natalie I. Vokes; Kelsey Pan; Xiuning Le

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · English · DOAJ Scopus

    For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a…

  2. Journal Article

    Current and future treatment options for exon 14 skipping alterations in non-small cell lung cancer

    Lingzhi Hong; Jianjun Zhang; John V. Heymach et al.

    Therapeutic Advances in Medical Oncology, Vol. 13 · 2021 · English · DOAJ Scopus

    It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting cancer growth and metastasis. MET exon 14 skipping ( METex14 ) alterations occur in 3–4% of all non-small cell lung cancer (NSCLC) patients…

  3. Journal Article

    Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer

    Lisha Ye; Wenjing Wang; Huihui Li et al.

    Therapeutic Advances in Medical Oncology, Vol. 16 · 2024 · English · DOAJ Scopus

    Non-small cell lung cancer (NSCLC) represents the most prevalent histological subtype of lung cancer. Within this disease, the MET gene emerges as a critical therapeutic target, exhibiting various forms of dysregulation. Although MET tyrosine kinase inhibitors, HGF/c-MET targeting antibodies, and…

  4. Journal Article

    Antibody-drug conjugates in lung cancer: dawn of a new era?

    Niamh Coleman; Timothy A. Yap; John V. Heymach et al.

    npj Precision Oncology, Vol. 7 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in modern drug development. By harnessing the powers of both cytotoxic chemotherapy and targeted therapy, ADCs are unique in offering the potential to deliver highly potent cytotoxic agents to cancer cells…

  5. Journal Article Full text

    Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

    Sonia A. Patel; Monique B. Nilsson; Xiuning Le et al.

    Clinical Cancer Research · 2022 · English · OpenAlex Scopus

    Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation, growth, and metastatic spread. The vascular network within the tumor facilitates the transport of nutrients…

  6. Journal Article

    Progress and challenges of artificial intelligence in lung cancer clinical translation

    Erjia Zhu; Amgad Muneer; Jianjun Zhang et al.

    npj Precision Oncology, Vol. 9 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Artificial intelligence (AI) algorithms, such as convolutional neural networks and transformers, have significantly impacted cancer care. For lung cancer, AI holds great potential in addressing smoking cessation, personalized screening, and imaging genomics. And these data could be…

  7. Journal Article Full text

    AI in drug discovery and its clinical relevance

    Rizwan Qureshi; Muhammad Faisal Irfan; Taimoor Muzaffar Gondal et al.

    Heliyon · 2023 · English · OpenAlex Scopus

    The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation in clinical settings is a long, complex, and expensive process, with many potential points of failure. Over the past decade, a vast growth…

    Also available at: DOAJ

  8. Journal Article

    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

    Xiuning Le; Monique B. Nilsson; Jonathan Wade Goldman et al.

    Journal of Thoracic Oncology · 2020 · English · OpenAlex Scopus

    The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream…

  9. Journal Article

    Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients

    Lingzhi Hong; Sonia Patel; Leylah M. Drusbosky et al.

    npj Precision Oncology, Vol. 8 No. 1 · 2024 · English · DOAJ Scopus

    Abstract ERBB2 (HER2) represents a newly recognized actionable oncogenic driver in non-small cell lung cancer (NSCLC), with approved targeted therapy available. Understanding the landscape of ERBB2 alterations and co-occurring mutations is essential for guiding treatment decisions. We conducted an…

  10. Journal Article

    Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context

    Yang Xia; Panwen Tian; Mo Zhou et al.

    EClinicalMedicine, Vol. 81 · 2025 · English · DOAJ Scopus

    Summary: Background: MET exon14 skipping mutations (METex14) is an established actionable driver oncogene of non-small-cell lung cancer (NSCLC). While ensartinib is a known second-generation tyrosine kinase inhibitor with primary activity against ALK translocation, it is also classified as a type…

  11. Journal Article

    Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening

    Sara Nofal; Jiangong Niu; Paul Resong et al.

    Cancer Medicine, Vol. 13 No. 5 · 2024 · English · DOAJ Scopus

    Abstract Background Personal history of cancer is an independent risk factor for lung cancer but is omitted from existing lung cancer screening eligibility criteria. In this study, we assess the lung cancer risk among cancer survivors and discuss potential implications for screening. Methods This…

  12. Journal Article

    Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib

    Mo Zhou; Yin Zhu; Xuqi Sun et al.

    npj Precision Oncology, Vol. 10 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Mesenchymal-epithelial transition exon 14 skipping mutations (METex14) define a targetable molecular subset of non-small cell lung cancer (NSCLC), but optimal circulating tumor DNA (ctDNA) biomarkers to guide MET tyrosine kinase inhibitor therapy remain undefined. Within the EMBRACE trial…

  13. Journal Article

    Targeting MET in NSCLC: An Ever-Expanding Territory

    Ying Han, MD; Yinghui Yu, MD; Da Miao, MD et al.

    JTO Clinical and Research Reports, Vol. 5 No. 2 · 2024 · English · DOAJ Scopus

    MET protooncogene (MET) alterations are known driver oncogenes in NSCLC. Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET…

  14. Journal Article

    Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood

    Yang Xia; Yin Zhu; Sai Zhang et al.

    Nature Communications, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Early detection of lung cancer is crucial for improving patient outcomes. However, accurately diagnosing invasive pulmonary nodules and predicting tumor invasiveness remain major clinical challenges. Given the established role of immune dysfunction in cancer development, we hypothesize…

  15. Journal Article

    The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

    Balazs Halmos; Narjust Florez; Sarah Goldberg et al.

    Oncology and Therapy, Vol. 13 No. 4 · 2025 · English · DOAJ Scopus

    Abstract Introduction In advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (Ex19del/L858R), intravenous amivantamab is approved for first-line treatment with lazertinib, and second-line treatment with carboplatin-pemetrexed. Subcutaneous…

  16. Journal Article

    Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson

    Jeong Uk Lim; Heather Y. Lin; Lei Kang et al.

    npj Precision Oncology, Vol. 10 No. 1 · 2026 · English · DOAJ Scopus

    Abstract We evaluated clinical outcomes and safety profiles in patients with non-small cell lung cancer (NSCLC) treated in early-phase trials. A retrospective review of 546 NSCLC cases treated from January 2016 to December 2024 at The University of Texas MD Anderson Cancer Center was performed…

  17. Journal Article

    Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

    Hui Li; Xin Hu; Matthew S. Ning et al.

    Frontiers in Oncology, Vol. 14 · 2024 · English · DOAJ Scopus

    Accurate diagnoses are crucial in determining the most effective treatment across different cancers. In challenging cases, morphology-based traditional pathology methods have important limitations, while molecular profiling can provide valuable information to guide clinical decisions. We present a…

  18. Journal Article

    Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

    Whitney E. Lewis, PharmD; Lingzhi Hong, MD, PhD; Frank E. Mott, MD et al.

    JTO Clinical and Research Reports, Vol. 2 No. 11 · 2021 · English · DOAJ Scopus

    Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We…